Journal article

CD73: A potential biomarker for anti-PD-1 therapy

PA Beavis, CY Slaney, N Milenkovski, MA Henderson, S Loi, J Stagg, MH Kershaw, PK Darcy

Oncoimmunology | Published : 2015

DOI: 10.1080/2162402X.2015.1046675

Abstract

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be overexpressed in several human cancers and A2A antagonists have undergone clinical trials for Parkinson's Disease, this combination warrants further investigation.

University of Melbourne Researchers

Paul Beavis Author

Clare Slaney Author

Sherene Loi Author

Phillip Darcy Author

Related Projects (4)

INVESTIGATING THE POTENTIAL OF ADENOSINE RECEPTOR BLOCKADE FOR THE TREATMENT OF BREAST CANCER

BLOCKING BREAST CANCER CELL TYPE I IFN SIGNALLING PREVENTS IMMUNE RECOGNITION AND ALLOWS METASTATIC PROGRESSION TO BONE

TARGETING THE ADENOSINE PATHWAY FOR ENHANCING CANCER THERAPY

We have shown that drugs that block immunosuppressive adenosine receptors can improve anti-tumour immune responses and consequently enhance ..

UTILIZATION OF GENE-ENGINEERED T CELLS FOR ENHANCING CANCER IMMUNOTHERAPY

Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form ..

Grants

Awarded by National Health and Medical Research Council

Citation metrics

31Web of Science

Keywords

Science & Technology

Neurodegenerative

Brain Disorders

Clinical Research

Life Sciences & Biomedicine

3204 Immunology

Parkinson'S Disease

32 Biomedical and Clinical Sciences

5.1 Pharmaceuticals